Abstract: A new metal organic framework (MOF) series and method of synthesizing the same are disclosed which includes an organic linking ligand having the formula: and a metal ion bonded to the organic linking ligand.

Abstract: The present invention relates to a method for producing one or more low molecular weight aromatic lignin-derived compounds. The method preferably comprises providing lignocellulosic material, subjecting the lignocellulosic material to a pulping process, separating pulp to provide a substantially pulp-free process stream comprising a modified lignin-derived component, isolating the modified lignin-derived component, subjecting the isolated modified lignin-derived component to a decomposition step comprising oxidative cracking (cracking and oxidizing) or reducing under the influence of a catalyst or electro-oxidation, and subjecting the resulting products to an isolation step, to provide a low molecular weight aromatic lignin-derived compound. Said compound may be further modified, e.g. by annulation. The inventive method preferably comprises further oxidizing said compound to a redox active compound.

Abstract: Disclosed are methods for the benzylic oxidation of the lignin and related compounds. The methods include contacting lignin with a mixture containing manganese and iron, in the presence of oxygen to produce a carboxylic acid from lignin or a related compound. In some embodiments, the mixture includes cobalt.

Abstract: The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more H or OH, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow.

Abstract: The present invention is directed generally to a method of production of value-added, biobased chemicals from lignin sources, including waste lignin. A method of producing biobased aromatic chemicals, biobased aromatic fuels, and/or lignin residues from lignin is also described herein.

Abstract: A resist composition containing a compound represented by general formula (m0), wherein R1 and R2 each independently represents an aryl group which may have a substituent, an alkyl group which may have a substituent, or an alkenyl group which may have a substituent, provided that R1 and R2 may be mutually bonded to form a ring with the sulfur atom; R3 represents an aromatic hydrocarbon group which may have a substituent, an alkenyl group which may have a substituent, or an alkynyl group which may have a substituent; V1 represents a single bond or an alkylene group, provided that, when R3 is an aromatic hydrocarbon group which may have a substituent, V1 is an alkylene group; and X0? represents a monovalent organic anion.

Abstract: A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group, an ethyl group or a straight or branched chain C3 to C20 alkyl group; x represents 0 or an integer from 1 to 4 and y represents 0 or an integer from 1 to 4, wherein the sum of x and y is 4; and Z represents a hydrogen atom or (HOR1)yR2XN+; compositions including the compound; use of the compound in the manufacture of a medicament; and methods of medical treatment including the topical application of the compound.

Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

Abstract: The present application relates to a method for inducing germination of a spore forming bacterium, specifically, a method for inducing germination of a spore forming bacterium, comprising: using one or more compounds having a phenolic backbone to induce germination of a spore forming bacterium selected from the group consisting of the genus Bacillus, the genus Geobacillus, and the genus Aeribacillus; to a germination inducer for a spore forming bacterium; and to a kit for use in germination of a spore forming bacterium.

Abstract: Provided is a method for selectively demethylating a 2-methoxy group. Specifically provided is a production method of a compound represented by formula (7) below through the following reactions.

Abstract: The present invention relates to Compounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR4R5, —NHC(?Y)R4, —NHC(?Y)NR5R?, —NHC(?O)OR4, —NHSO2R4, C(?Y)NR4R5, C(?O)OR6 [wherein Y is oxygen or sulphur], OR5, —O(C?O)NR4R5, O-acyl, S(O)mR4, —SO2N(R4)2, cyano, amidino or guanidino [wherein R4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R5 is hydrogen or R4; Rx is R4 or —SO2N(R4)2 and R6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR4, —OC(?O)NR4R5, O-acyl, NH2, NR4R5, —NHC(?Y)R4, —NHC(?Y)NR5Rx, —NHC(?O)OR4, —NHSO2R4, and to processes for t

Abstract: Here is provided a charge control resin which is prompt in charge rising up, excellent in electrostatic charging propensity and easy in manufacturing. This charge control resin contains a polymer as an active ingredient having a constituent unit represented by following Formula (1) in the Formula (1), R1 is independent of one another, and is a hydrogen atom, a hydroxyl group, a halogen atom, a carboxy-containing group, a straight-chained or branched alkyl group having 1-18 carbon atoms, or a straight-chained or branched alkoxy group having 1-18 carbon atoms; R2 is a hydrogen atom, a hydroxyl group, a halogen atom, a carboxy-containing group, a straight-chained or branched alkyl group having 1-18 carbon atoms, or a straight-chained or branched alkoxy group having 1-18 carbon atoms; g is a number of 1-3; h is a number of 1-3; and M is a hydrogen atom, an alkali metal, a straight-chained or branched alkyl group having 1-18 carbon atoms, an ammonium radical or a mixture of any of these.

Abstract: Described are acetylene bridged linkers, metal-organic frameworks produced thereof, processes for producing the linkers and the metal-organic frameworks, and the use of the metal-organic frameworks. The metal-organic frameworks possess an enhanced ability to adsorb and desorb high amounts of gases, in particular methane or hydrogen. The metal-organic frameworks have a high porosity and, thus, a high inner surface.

Abstract: A method of biologically producing p-hydroxybenzoic acid, and a method for producing p-hydroxybenzoic acid from lignin through chemical and biological conversion.

Abstract: Provided is a method for selectively demethylating a 2-methoxy group. Specifically provided is a production method of a compound represented by formula (7) below through the following reactions.

Abstract: A pharmaceutical composition including at least one compound of the Formulas (I), (II), or (III), or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, as defined herein. Also disclosed is a method of treatment of diseases which are pathophysiologically related to GPR35, the GPR35-hERG signaling complex, or both, as defined herein.

Abstract: Provided is a method for effectively producing a 4,5-dialkoxy-2-hydroxybenzoic acid from an inexpensive raw material. A method for producing a 2-bromo-4,5-dialkoxybenzoic acid represented by the following formula (2): (wherein each of R1 and R2 represents a lower alkyl group), the method including causing a 3,4-dialkoxybenzoic acid represented by the following formula (1): (wherein R1 and R2 have the same meanings as defined above) to react with bromine in concentrated hydrochloric acid.

Abstract: The present invention provides a composition comprising a chelating agent and unheated cashew nut shell liquid.

Abstract: A method for utilizing agricultural biomass components, namely cellulose, hemicellose, and lignin, and converting them to value-added biobased chemical products is described herein. The present method provides treatments to obtain a plurality of component streams from agricultural biomass for producing derivative products while minimizing waste products.

Abstract: A method for utilizing woody biomass components, namely cellulose, hemicellose, and lignin, and converting them to value-added biobased chemical products is described herein. The present method provides treatments to obtain a plurality of component streams from woody biomass for producing derivative products while minimizing waste products.

Abstract: A method for utilizing biomass components, namely cellulose, hemicellose, and lignin, and converting them to value-added biobased chemical products is described herein. The present method provides treatments to obtain a plurality of component streams from biomass for producing derivative products while minimizing waste products.

Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.

Abstract: A novel functionally effective organic molecules with various molecular weights are produced by cleaving lignite with hydrogen peroxide or alkaline hydrogen peroxide predominantly below 1000 molecular weight, the said functionally effective organic molecules, molecular weights varies depending on the reaction conditions such as concentration of hydrogen peroxide, time of reaction, temperature, ratio of lignite to hydrogen peroxide, lignite quality etc. conditions. These organic molecules are functionally effective than normal organic molecules (humic, fulvic acids etc.) present naturally in lignite or leonardite due to enhanced reactive nature obtained by treating with hydrogen peroxide or alkaline hydrogen peroxide which are resultant of cleavage of lignite. These functionally effective organic molecules have utilities in various areas such as agriculture and medicine.

Abstract: The present invention provides a composition comprising one or more acids and a non-heated cashew nut shell liquid, wherein decarboxylation of an anacardic acid in the non-heated cashew nut is inhibited by the one or more acids.

Abstract: Disclosed herein is a process for the preparation of highly pure 2,6-diisopropyl phenol (Formula I), which comprises reacting p-hydroxy benzoic acid (Formula II) with an alkylating agent in presence of aq. mineral acid followed by basilication and subsequent washings to yield 4-hydroxy-3,5-diisopropylbenzoic acid (Formula III) free of dimer impurity, 4, 4?-oxy-dibenzoic acid of Formula IV, ether impurity 3,5-di(propan-2-yl)-4-(propan-2-yloxy)benzoic acid of Formula V and the monoalkylated impurity 4-hydroxy-3-(propan-2-yl) benzoic acid of Formula VI; and decarboxylating 4-hydroxy-3,5-diisopropylbenzoic acid (Formula III) in presence of high boiling solvent and sodium hydroxide as a catalyst at high temperature to yield 2,6-diisopropyl phenol substantially free of ether impurity 1,3-di(propan-2-yl)-2-(propan-2-yloxy)benzene of Formula VII and monoalkylated phenol impurity 2-(propan-2-yl) phenol of Formula VIII. Propofol prepared by the process of the present invention is suitable for pharmaceutical use.

Abstract: The present invention provides a novel compound that makes it possible to improve ionization efficiency of hydrophobic peptide. 5-alkoxy-2- or -3-hydroxybenzoic acid represented by the following formula (I): where R is an alkyl group having 6 to 10 carbon atoms and the substituted carboxyl group and hydroxyl group are ortho or meta to each other. A matrix additive for mass spectrometry, which is represented by the above formula (I). The above additive which is added to a matrix for mass spectrometry selected from the group consisting of ?-cyano-4-hydroxycinnamic acid, 2,5-dihydroxybenzoic acid, sinapic acid, and 1,5-diaminonaphthalene. The above additive which is used for mass spectrometry of a hydrophobic peptide.

Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.

Abstract: Methods for identifying MarR family inhibiting compounds are described. The methods include the use of computer aided rational based drug design programs and three dimensional structures of MarR family polypeptides.

Abstract: Phosphonium-based room temperature ionic liquids (“RTILs”) were prepared. They were used as matrices for Matrix-Assisted Laser Desorption Ionization (MALDI) mass spectrometry and also for preparing samples of dyes for analysis.

Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: Are described compounds of Formula (I) in which R, R?, R?, A, and D have the meanings described in the text, as useful agents in the cure of pathologies characterized by altered angiogenesis and as antitumorals.

Abstract: [Problem] To provide a method of producing an aromatic amino compound by using a primary or secondary amine compound and a halogenated aromatic compound as starting materials, and relying upon the Ullmann reaction, the method being capable of obtaining the highly pure aromatic amino compound in high yields and inexpensively.

Abstract: The present invention relates generally to the use of plants as bioreactors for the production of molecules having useful properties such as inter alia polymers, metabolites, proteins, pharmaceuticals and nutraceuticals. More particularly, the present invention contemplates the use of grasses, and even more particularly C4 grasses, such as sugarcane, for the production of a range of compounds such as, for example, polyhydroxyalkanoates, pHBA, vanillin, indigo, adipic acid, 2-phenylethanol, 1,3-propanediol, sorbitol, fructan polymers and lactic acid as well as other products including, inter alia, other plastics, silks, carbohydrates, therapeutic and nutraceutic proteins and antibodies. The present invention further extends to transgenic plants and, in particular, transgenic C4 grass plants, capable of producing the compounds noted above and other products, and to methods for generating such plants.

Abstract: The invention relates to a novel mediator used in the production of wood composite materials that are devoid of binding agents.

Abstract: An overbased salt of an oligomerized alkylhydroxyaromatic compound is disclosed, wherein the alkyl group of the alkylhydroxyaromatic compound is derived from an olefin mixture comprising propylene oligomers having an initial boiling point of at least about 195° C. and a final boiling point of no more than about 325° C. as measured by ASTM D86. Also disclosed is a lubricating oil composition containing at least (a) a major amount of an oil of lubricating viscosity and (b) the overbased salt of the oligomerized alkylhydroxyaromatic compound.

Abstract: The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.

Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

Abstract: The present invention relates to an acid salt of tolterodine with superior stabililty and useful as a transdermal drug delivery system. More specifically, the present invention relates to a novel acid salt of tolterodine with superior stabililty to the conventional acid salts of tolterodine, which is useful as a pharmaceutical composition for the treatment of overactive bladder and can be formulated into a transdermal drug delivery system.

Abstract: A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group, an ethyl group or a straight or branched chain C3 to C20 alkyl group; x represents 0 or an integer from 1 to 4 and y represents 0 or an integer from 1 to 4, wherein the sum of x and y is 4; and Z represents a hydrogen atom or (HOR1)yR2XN+; compositions including the compound; use of the compound in the manufacture of a medicament; and methods of medical treatment including the topical application of the compound.

Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.

Abstract: This invention relates to novel compounds useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.

Abstract: The invention provides a methioninase inhibitor to suppress the production of methyl mercaptan that is a causative substance of a bad smell by inhibiting methioninase originated from bacteria, as well as a composition and a food or drink containing the same, wherein the methioninase inhibitor contains an extract obtained from a plant of the family Myrsinaceae, genus Myrsine, preferably Myrsine seguinii as an active ingredient; and further provides a methioninase inhibitor, as well as a composition and a food or drink containing the same, wherein the methioninase inhibitor contains as an active ingredient one or more selected from the group consisting of myrsinoic acid A, myrsinoic acid B, myrsinoic acid C, myrsinoic acid E and myrsinoic acid F; preferably the myrsinoic acid A, myrsinoic acid B, myrsinoic acid C, myrsinoic acid E and myrsinoic acid F are obtained from a plant of the family Myrsinaceae, genus Myrsine, preferably Myrsine seguinii.

Abstract: Disclosed is an amide compound represented by the formula (1) below, which has excellent plant disease controlling activity. In the formula, X1 represents a fluorine atom or a methoxy group; X2 represents a hydrogen atom, a halogen atom, a C1-C4 alkyl group or the like; X3 represents a halogen atom, a C1-C4 alkyl group or the like; Z represents an oxygen atom or a sulfur atom; and A represents an A1-CR11R12R13 group, an A2-Cy1 group or an A3-Cy2 group, wherein A1 represents a CH2 group or the like, A2 represents a single bond, a CH2 group or the like, A3 represents a C1-C3 haloalkyl group, a C2-C4 alkenyl group or the like, Cy1 represents a C3-C6 cycloalkyl group substituted with a C1-C6 alkoxy group or the like, Cy2 represents a C3-C6 cycloalkyl group which may be substituted with a halogen atom or the like, R11 and R12 independently represent a C1-C4 alkyl group, and R13 represents a halogen atom, a hydroxyl group or the like.

Abstract: Ethers of aromatic acids are produced from halogenated aromatic acids in a reaction mixture containing a copper (I) or copper (II) source and an amino acid ligand that coordinates to copper.

Abstract: Hydroxy aromatic acids are produced in high yields and high purity (>95%) from halogenated aromatic acids in a reaction mixture containing a copper source and a ligand that coordinates to copper.

Abstract: The invention relates to a process for the preparation of a compound of the general formula (I) in which a) a compound (II) is reacted in the presence of a base B1 with a compound (III) and b) the compound (IV) formed as intermediate in step a) is reacted in the presence of a base B2 with a compound (V) to give the compound of the general formula (I)

Abstract: The invention relates to novel compositions comprising a phenolic compound as well as to the use of these compositions as a medicament, in particular for the manufacture of a nutraceutical or pharmaceutical composition for the treatment, co-treatment or prevention of inflammatory disorders, such as arthritis, asthma, inflammatory bowel diseases, inflammatory diseases of the skin (e.g., psoriasis, eczema, atopic dermatitis, sunburn) and chronic inflammatory disorders, such as atherosclerosis, heart diseases, metabolic syndrome X, cancer, Alzheimer's disease and pre-stages thereof such as mild cognitive impairment. Also, the invention relates to the use of a cosmetic composition comprising a phenolic compound for the cosmetic treatment, co-treatment or prevention of inflammation of the skin, in particular for the cosmetic treatment, co-treatment or prevention of sunburn or of impure skin.

Abstract: The present invention provides a method for producing a compound represented by the formula (3): wherein n is an integer of 1 to 6, characterized by the steps of hydrolyzing a solution containing an ester compound represented by the formula (1): wherein R is a lower alkyl group and n is an integer of 1 to 6, and a compound represented by the formula (2): wherein R is as defined above, adjusting the pH of the resulting solution to pH 4 to 8, and then subjecting to phase separation to obtain an organic layer containing the carboxylic acid of formula (3).

Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: Hydroxy aromatic acids are produced in high yields and high purity (>95%) from halogenated aromatic acids in a reaction mixture containing a copper source and a ligand that coordinates to copper.